Is VCYT a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Veracyte (VCYT) rests on Decipher prostate franchise: Decipher is the largest and fastest-growing revenue line, up roughly 30% year over year in Q1 2026 to about $87M in testing revenue. Revenue (TTM) is ~$517M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. Whether VCYT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Veracyte is a US genomic diagnostics company that develops and runs advanced molecular tests used to guide cancer treatment decisions. Its two flagship products drive the business: Decipher, a genomic classifier for prostate cancer, and Afirma, which helps assess indeterminate thyroid nodules to avoid unnecessary surgeries. The company also markets tests in other areas and runs a research platform (Afirma GRID, Decipher studies) built on large proprietary genomic sample databases that act as a competitive moat. Testing revenue is the dominant and fastest-growing part of the mix. The investment picture is one of a diagnostics company that has crossed into sustained profitability, a relative rarity in the space. Q1 2026 revenue rose roughly 21% year over year to about $139M with GAAP net income of about $29M and an adjusted EBITDA margin near 31%, and management raised full-year guidance. The tradeoff is valuation: the stock carries a P/E in the mid-40s and a market cap around $4.6B, so much of the near-term growth is already priced in, and the concentration in two tests plus reimbursement dependence are the key things to weigh.
What's the case for buying VCYT?
1. Decipher prostate franchise
Decipher is the largest and fastest-growing revenue line, up roughly 30% year over year in Q1 2026 to about $87M in testing revenue. Expanding clinical guideline inclusion and use across more stages of prostate cancer support continued double-digit volume growth.
2. Afirma thyroid dominance
Afirma is used by a large share of US endocrinologists and is close to synonymous with thyroid nodule assessment. It grew about 21% in Q1 2026, and add-on features like the Xpression Atlas extend it toward therapy-selection use cases.
3. Sustained profitability and cash generation
Veracyte has shifted from cash-burning to consistently profitable, with adjusted EBITDA margins near 30% and rising full-year guidance. That self-funding profile lets it invest in new tests and studies without diluting shareholders heavily.
4. Pipeline and new test expansion
The company is investing in new assays (including tissue and blood-based tests) and expanding Decipher and Afirma indications. New-test contributions are framed as upside on top of the mid-teens core testing growth.
What are the risks to VCYT?
Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The stock trades at a premium valuation (P/E in the mid-40s), which amplifies downside if growth decelerates or guidance is missed. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches and international expansion carry execution and regulatory risk.
How is VCYT valued? (as of July 2026)
Snapshot for VCYT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$517M
- Q1 2026 revenue: ~$139M (up ~21% YoY)
- Net income (TTM): ~$66M
- 2026 revenue guidance: ~$582M to $592M
- Market cap: ~$4.6B
- P/E (trailing): ~45x
Veracyte is profitable on a GAAP basis with an adjusted EBITDA margin near 31% in Q1 2026, an uncommon profile among growth-stage diagnostics firms. The mid-40s P/E sits well above the broader biotech average, reflecting the market pricing in continued double-digit testing growth. Figures are approximate and drawn from the most recent reported quarter and guidance.
How do you decide if VCYT is a buy?
Rather than asking whether VCYT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold VCYT indirectly through an index or sector ETF before adding more.
For the full picture, see the VCYT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about VCYT against your real portfolio and see your actual exposure before deciding.
The bottom line on VCYT
The bottom line: Veracyte's story right now is Decipher prostate franchise, with revenue (ttm) at ~$517M. If you believe that narrative continues, the call is about sizing VCYT sensibly and checking overlap with what you own; if you doubt it (the risk: revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on VCYT
- VCYT stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- VCYT stock forecast (the drivers and risks shaping the outlook)
- Does VCYT pay a dividend?
Build a basket around VCYT with Walnut
Use Veracyte as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is VCYT a good stock to buy right now?
+
The case for Veracyte right now is Decipher prostate franchise, with revenue (ttm) at ~$517M. If you believe that thesis holds, VCYT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Veracyte do?
+
Veracyte is a US genomic diagnostics company that develops and runs advanced molecular tests used to guide cancer treatment decisions.
What are the main risks of VCYT?
+
Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The stock trades at a premium valuation (P/E in the mid-40s), which amplifies downside if growth decelerates or guidance is missed. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches and international expansion carry execution and regulatory risk.
What does Veracyte do?
+
Veracyte is a genomic diagnostics company that develops and runs molecular tests used to guide cancer treatment decisions. Its main products are Decipher for prostate cancer and Afirma for thyroid nodule assessment.
Is Veracyte profitable?
+
Yes. As of Q1 2026 Veracyte reports GAAP net income (about $29M in the quarter) and an adjusted EBITDA margin near 31%, making it one of the more consistently profitable growth-stage diagnostics companies.
What are Veracyte's two main products?
+
Decipher, a genomic classifier for prostate cancer, is the largest and fastest-growing test, and Afirma, which assesses indeterminate thyroid nodules to help avoid unnecessary surgery, is the second core franchise.
How fast is Veracyte growing?
+
Q1 2026 revenue rose about 21% year over year to roughly $139M, with Decipher up around 30% and Afirma up around 21%. Full-year 2026 guidance implies continued double-digit growth.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell VCYT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.